別名: LM-1149 , CYT11387 中文名稱:莫莫替尼,莫洛替尼
此產品請避光密封保存。
Momelotinib (CYT387, LM-1149 , CYT11387) 是一種ATP競爭性JAK1/JAK2抑制劑,IC50為11 nM/18 nM,比作用于JAK3選擇性約高10倍左右。Momelotinib (CYT387) 可誘導凋亡和自噬。Phase 3。
Momelotinib (CYT387) Chemical Structure
CAS: 1056634-68-4
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
CTLL-2 | Antiproliferative assay | 72 hrs | Antiproliferative activity against IL-2-stimulated mouse CTLL-2 cells expressing JAK1/JAK3 after 72 hrs by alamar blue assay, IC50=1.249μM. | 19762238 | |
BAF3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against mouse BAF3 cells expressing TEL-JAK2 kinase after 72 hrs by alamar blue assay, IC50=0.798μM. | 19762238 | |
SET2 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SET2 cells expressing JAK2 V617F mutant kinase after 72 hrs by alamar blue assay, IC50=0.232μM. | 19762238 | |
BAF3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against mouse BAF3 cells expressing wild type JAK2 kinase after 72 hrs by alamar blue assay in presence of IL-3, IC50=1.43μM. | 19762238 | |
HEL 92.1.7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HEL 92.1.7 cells expressing JAK2 V617F mutant kinase after 72 hrs by alamar blue assay, IC50=1.804μM. | 19762238 | |
HEL | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay, IC50=2.3μM. | 29940115 | |
BAF3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against mouse BAF3 cells expressing TEL-JAK3 kinase after 72 hrs by alamar blue assay, IC50=2.425μM. | 19762238 | |
K562 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay, IC50=6.5μM. | 29940115 | |
HL60 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay, IC50=8.3μM. | 29940115 | |
DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
BAF3 | Function assay | Inhibition of JAK2 V617F mutant in mouse BAF3 cells, IC50=1.5μM. | ChEMBL | ||
點擊查看更多細胞系數據 |
產品描述 | Momelotinib (CYT387, LM-1149 , CYT11387) 是一種ATP競爭性JAK1/JAK2抑制劑,IC50為11 nM/18 nM,比作用于JAK3選擇性約高10倍左右。Momelotinib (CYT387) 可誘導凋亡和自噬。Phase 3。 | ||||||
---|---|---|---|---|---|---|---|
特性 | CYT387是ATP競爭性小分子JAK1 和JAK2抑制劑。 | ||||||
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | CYT387有效且選擇性作用于JAK1和JAK2,IC50分別為11 nM和 18 nM, 效果比作用于密切相關的JAK3激酶(IC50為155 nM)高9倍。在體外, CYT387抑制IL-3 刺激的 親本Ba/F3細胞(Ba/F3-wt) 增殖,IC50為1400 nM。而且, CYT387 作用于組成型激活的 JAK2 或 MPL信號 的細胞系,包括 Ba/F3-MPLW515L細胞, CHRF-288-11 細胞,和Ba/F3-TEL-JAK2細胞,也抑制細胞增殖,IC50分別為200 nM, 1 nM 和 700 nM。此外,CYT387在體外抑制JAK2V617F陽性PV患者的紅系集落生長具有相似效果,IC50為2μ-4 μM。[1] 最新研究顯示CYT387抑制IL-6 和IGF-1誘導的PI3K/AKT和Ras/MAPK信號。而且, CYT387 單獨用藥,以及和傳統抗MM 治療藥Bortezomib和Melphalan 聯用作用于原發(fā)性多發(fā)骨髓瘤(MM)細胞,誘發(fā)細胞凋亡。[2] | |||
---|---|---|---|---|
激酶實驗 | 無細胞激酶活性檢測實驗測定IC50值 | |||
在肽底物磷酸化實驗之前,純化在昆蟲細胞中表達的谷胱甘肽-S-轉移酶(GST)標標記的JAK激酶域。在384孔板上,使用Alphascreen 蛋白酪氨酸激酶P100檢測試劑盒和PerkinElmer Fusion Alpha儀器進行檢測實驗。 | ||||
細胞實驗 | 細胞系 | Ba/F3, Ba/F3-JAK2V617F 和Ba/F3-MPLW515L | ||
濃度 | 0 到10 μM | |||
孵育時間 | 72 小時 | |||
方法 | 使用表達 JAK2V617F (Ba/F3-JAK2V617F) 和MPLW515L (Ba/F3-MPLW515L) 突變型的Ba/F3細胞, 以及CHRF-288-11(JAK2T875N)和CMK(JAK3A572V)細胞。獲得TEL/JAK2和 TEL/JAK3融合,然后引進Ba/F3 鼠科細胞中。TEL/JAK2- 或 TEL/JAK3-轉染的細胞培養(yǎng)在含10%胎牛血清(FCS)的DMEM培養(yǎng)基上。Ba/F3 野生型細胞培養(yǎng)在含 10% FCS 及5 ng/mL 鼠 IL-3的RPMI培養(yǎng)基上。在37oC 下 5% CO2環(huán)境中溫育72小時,然后通過Alamar Blue檢測實驗測定增殖。 | |||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | p-JAK2 / JAK2 / p-STAT3 / STAT3 p-Src / Src | 26625308 | ||
Immunofluorescence | p62 / pS6 | 29138276 | ||
Growth inhibition assay | Cell viability | 20385788 |
體內研究(In Vivo) | ||
體內研究活性 | CYT387作用于鼠MPN 模型,使白細胞數,血球密度, 脾臟大小正?;?且恢復炎性細胞因子生理水平。[3] | |
---|---|---|
動物實驗 | Animal Models | 移植了轉導JAK2V617F 逆轉錄病毒的骨髓的Balb/c 小鼠 |
Dosages | ≤50 mg/kg | |
Administration | 口服處理 |
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT01236638 | Completed | Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis |
Sierra Oncology LLC - a GSK company |
November 2010 | Phase 2 |
NCT00935987 | Completed | Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis |
Sierra Oncology LLC - a GSK company |
November 2009 | Phase 1|Phase 2 |
分子量 | 414.46 | 分子式 | C23H22N6O2 |
CAS號 | 1056634-68-4 | SDF | Download Momelotinib (CYT387) SDF |
Smiles | C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N | ||
儲存條件(自收到貨起) | 3年 -20°C(避光) 粉狀 | ||
體外溶解度 |
DMSO : 83 mg/mL ( (200.26 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內溶解度 現配現用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內配方計算器 |
動物體內配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯系Selleck為您提供正確的澄清溶液配方)
計算結果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯系Selleck);
體內配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術支持郵箱tech@selleck.cn,直接聯系到我們。我們會在24小時內盡快聯系您。
如果有其他問題,請給我們留言。
* 必填項